NIKKEI 225
38,079.70 +117.90 (+0.31%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.62 -0.11 (-0.13%) GOLD FUTURES
2,394.20 -3.80 (-0.16%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
51,102.96 +1,497.45 (+3.02%)
The Cooper Companies, Inc. (COO)
After hours:
| Previous close | 89.86 |
| Open | 89.70 |
| Bid | 90.36 x 200 |
| Ask | 90.45 x 200 |
| Day's range | 89.41 - 90.80 |
| 52-week range | 75.93 - 104.07 |
| Volume | |
| Avg. volume | 1,123,156 |
| Market cap | 17.97B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 61.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.02 (0.02%) |
| Ex-dividend date | 26 Jul 2023 |
| 1y target est | N/A |
- GlobeNewswire
CooperCompanies Announces First Quarter 2024 Results
SAN RAMON, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. Revenue increased 9% year-over-year to $931.6 million. CooperVision (CVI) revenue up 7% to $621.5 million, and CooperSurgical (CSI) revenue up 12% to $310.1 million.GAAP diluted earnings per share (EPS) of $0.41, down $0.02 or 5% from last year's first quarter.Non-GAAP diluted EPS of $0.
- GlobeNewswire
CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)
SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”. The stock split supports Cooper’s desire to make ownership of its stock more accessible to employees and investors. Cooper previously announced on i
- PR Newswire
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.
